179 related articles for article (PubMed ID: 35217792)
21.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
22. Single-cell transcriptomics of NRAS-mutated melanoma transitioning to drug resistance reveals P2RX7 as an indicator of early drug response.
Randic T; Magni S; Philippidou D; Margue C; Grzyb K; Preis JR; Wroblewska JP; Nazarov PV; Mittelbronn M; Frauenknecht KBM; Skupin A; Kreis S
Cell Rep; 2023 Jul; 42(7):112696. PubMed ID: 37379213
[TBL] [Abstract][Full Text] [Related]
23. GAB2 induces tumor angiogenesis in NRAS-driven melanoma.
Yang Y; Wu J; Demir A; Castillo-Martin M; Melamed RD; Zhang G; Fukunaga-Kanabis M; Perez-Lorenzo R; Zheng B; Silvers DN; Brunner G; Wang S; Rabadan R; Cordon-Cardo C; Celebi JT
Oncogene; 2013 Aug; 32(31):3627-37. PubMed ID: 22926523
[TBL] [Abstract][Full Text] [Related]
24. Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy.
Demirci H; Demirci FY; Ciftci S; Elner VM; Wu YM; Ning Y; Chinnaiyan A; Robinson DR
JAMA Ophthalmol; 2019 Dec; 137(12):1444-1448. PubMed ID: 31647501
[TBL] [Abstract][Full Text] [Related]
25. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
Adam C; Fusi L; Weiss N; Goller SG; Meder K; Frings VG; Kneitz H; Goebeler M; Houben R; Schrama D; Schmidt M
J Invest Dermatol; 2020 Dec; 140(12):2455-2465.e10. PubMed ID: 32376279
[TBL] [Abstract][Full Text] [Related]
26. A Preexisting Rare
Romano G; Chen PL; Song P; McQuade JL; Liang RJ; Liu M; Roh W; Duose DY; Carapeto FCL; Li J; Teh JLF; Aplin AE; Chen M; Zhang J; Lazar AJ; Davies MA; Futreal PA; Amaria RN; Zhang DY; Wargo JA; Kwong LN
Cancer Discov; 2018 May; 8(5):556-567. PubMed ID: 29496665
[TBL] [Abstract][Full Text] [Related]
27. Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition.
Nguyen MQ; Teh JLF; Purwin TJ; Chervoneva I; Davies MA; Nathanson KL; Cheng PF; Levesque MP; Dummer R; Aplin AE
J Invest Dermatol; 2020 Nov; 140(11):2242-2252.e7. PubMed ID: 32389536
[TBL] [Abstract][Full Text] [Related]
28. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
[TBL] [Abstract][Full Text] [Related]
29. An overview of binimetinib for the treatment of melanoma.
Specenier P
Expert Opin Pharmacother; 2020 May; 21(7):747-754. PubMed ID: 32100585
[TBL] [Abstract][Full Text] [Related]
30. MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study.
Salzmann M; Pawlowski J; Loquai C; Rafei-Shamsabadi DA; Meiss F; Ugurel S; Schadendorf D; Meier F; Enk AH; Hassel JC
Eur J Cancer; 2022 May; 166():24-32. PubMed ID: 35272084
[TBL] [Abstract][Full Text] [Related]
31. Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.
Delyon J; Lebbe C; Dumaz N
Curr Opin Oncol; 2020 Mar; 32(2):79-84. PubMed ID: 31833955
[TBL] [Abstract][Full Text] [Related]
32. Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis.
Krisp C; Parker R; Pascovici D; Hayward NK; Wilmott JS; Thompson JF; Mann GJ; Long GV; Scolyer RA; Molloy MP
Br J Cancer; 2018 Sep; 119(6):713-723. PubMed ID: 30116025
[TBL] [Abstract][Full Text] [Related]
33. Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.
Malka-Mahieu H; Girault I; Rubington M; Leriche M; Welsch C; Kamsu-Kom N; Zhao Q; Desaubry L; Vagner S; Robert C
Cell Cycle; 2016 Sep; 15(18):2405-9. PubMed ID: 27533468
[TBL] [Abstract][Full Text] [Related]
34. NRAS
Banik I; Cheng PF; Dooley CM; Travnickova J; Merteroglu M; Dummer R; Patton EE; Busch-Nentwich EM; Levesque MP
Pigment Cell Melanoma Res; 2021 Mar; 34(2):150-162. PubMed ID: 32910840
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.
Yin C; Zhu B; Zhang T; Liu T; Chen S; Liu Y; Li X; Miao X; Li S; Mi X; Zhang J; Li L; Wei G; Xu ZX; Gao X; Huang C; Wei Z; Goding CR; Wang P; Deng X; Cui R
Cell; 2019 Feb; 176(5):1113-1127.e16. PubMed ID: 30712867
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
[TBL] [Abstract][Full Text] [Related]
37. E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis.
Montagnani V; Maresca L; Apollo A; Pepe S; Carr RM; Fernandez-Zapico ME; Stecca B
J Biol Chem; 2020 Nov; 295(47):16058-16071. PubMed ID: 32938713
[TBL] [Abstract][Full Text] [Related]
38. NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth.
Cai C; Tu J; Najarro J; Zhang R; Fan H; Zhang FQ; Li J; Xie Z; Su R; Dong L; Arellano N; Ciboddo M; Elf SE; Gao X; Chen J; Wu R
Mol Cancer Res; 2024 Apr; 22(4):386-401. PubMed ID: 38294692
[TBL] [Abstract][Full Text] [Related]
39. Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma.
Potu H; Peterson LF; Kandarpa M; Pal A; Sun H; Durham A; Harms PW; Hollenhorst PC; Eskiocak U; Talpaz M; Donato NJ
Nat Commun; 2017 Feb; 8():14449. PubMed ID: 28198367
[TBL] [Abstract][Full Text] [Related]
40. Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.
Manca A; Lissia A; Capone M; Ascierto PA; Botti G; Caracò C; Stanganelli I; Colombino M; Sini M; Cossu A; Palmieri G
J Transl Med; 2015 Jan; 13():37. PubMed ID: 25627962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]